KR960014121A - 아로일-피페리딘 유도체 - Google Patents

아로일-피페리딘 유도체 Download PDF

Info

Publication number
KR960014121A
KR960014121A KR1019950035296A KR19950035296A KR960014121A KR 960014121 A KR960014121 A KR 960014121A KR 1019950035296 A KR1019950035296 A KR 1019950035296A KR 19950035296 A KR19950035296 A KR 19950035296A KR 960014121 A KR960014121 A KR 960014121A
Authority
KR
South Korea
Prior art keywords
compound
salt
formula
benzoyl
benzyl
Prior art date
Application number
KR1019950035296A
Other languages
English (en)
Other versions
KR100413985B1 (ko
Inventor
오프네르 질비오
자코프 베엔스트라 지엠
쉴링 발테르
Original Assignee
베르너 발데크
시바-가이기 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데크, 시바-가이기 아게 filed Critical 베르너 발데크
Publication of KR960014121A publication Critical patent/KR960014121A/ko
Application granted granted Critical
Publication of KR100413985B1 publication Critical patent/KR100413985B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Insulating Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Suspension Of Electric Lines Or Cables (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

본 발명은 하기 일반식(I)의 신규한 N-(3,5-비스-트리플루오로메틸-벤조일)-2-벤질-4-(아자나프토일-아미노)-피페리딘 및 그의 염, 그의 용도, 그의 제조 방법 및 본 발명에 따른 화합물 또는 그의 제약상 허용되는 염을 포함하는 제약 조성물에 관한 것이다.
상기 식 중, X 및 Y는 각각 독립해서 다른 N 및 (또는) CH이고, 고리 A는 비치환되거나 또는 저급 알킬, 저급 알콕시, 할로겐, 니트로 및 트리플루오로메틸로 구성되는 군으로부터 선택되는 치환체에 의해 일- 또는 다-치환되는 것이다.

Description

아로일-피페리딘 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 일반식(I)의 화합물 또는 그의 염.
    상기 식 중, X 및 Y는 각각 독립해서 다른 N 및 (또는) CH이고, 고리 A는 비치환되거나 또는 저급 알킬, 저급 알콕시, 할로겐, 니트로 및 트리플루오로메틸로 구성되는 군으로부터 선택되는 치환체에 의해 일- 또는 다-치환되는 것이다.
  2. 제1항에 있어서, 하기 일반식(IA)의 화합물 및 그의 염.
    상기 식 중, X는 CH 또는 N이고, Y는 N이며, Z는 수소, 할로겐 또는 니트로이다.
  3. 제2항에 있어서, X는N 또는 CH이고, Y는 X이며, X는 할로겐인 일반식 (IA)의 화합물 또는 그의 염.
  4. (2R, 4S)-N-〔1-(3,5-비스-트리풀루오로메틸-벤조일)-2-벤질-피페리딘-4-일〕-퀴놀린-4-카르복스아미드, (2R, 4S)-N-〔1-(3,5-비스-트리플루오로메틸-벤조일)-2-벤질-피페리딘-4-일〕-퀴나졸린-4-카르복스아미드, (2R, 4S)-N-〔1-(3,5-비스-트리풀루오로메틸-벤조일)-2-(4-클로로-벤질)-피페리딘-4-일〕-퀴놀린-4-카르복스아미드, (2R, 4S)-N-〔1-(3,5-비스-트리플루오로메틸-벤조일)-2-(4-클로로-벤질)-피페리딘-4-일〕-퀴나졸린-4-카르복스아미드, (2R, 4S)-N-〔1-(3,5-비스-트리플루오로메틸-벤조일)-2-(4-클로로-벤질)-피페리딘-4-일〕-이소퀴놀린-4-카르복스아미드 및 (2R, 4S)-N-〔1-(3,5-비스-트리플루오로메틸-벤조일)-2-(4-니트로-벤질)-피페리딘-4-일〕-퀴나졸린-4-카르복스아미드로 이루어지는 군으로 부터 선택되는 화합물 또는 그의 염.
  5. 사람 또는 동물의 신체를 치료하는 방법에 사용하기 위한 제1항 내지 제4항 중 어느 한 항에 따른 화합물 또는 그의 제약상 허용되는 염.
  6. 제1항 내지 제4항 중 어느 한 항에 따른 화합물 또는 그의 제약상 허용되는 염을 포함하는 제약 조성물.
  7. 물질 P에 의해 유발되는 질환을 치료하기 위한 제약 조성물 제조시 제1항 내지 제4항 중 어느 한 항에 따른 화합물의 용도
  8. a) 하기 일반식 (IIa)의 화합물을 하기 일반식(IIb)의 화합물 또는 그의 염과 반응시키거나, 또는
    (식 중, X 및 Y는 제1항에서 정의된 바와 같고, 고리 A는 비치환되건 또는 제1항에서 기술된 바와 같이 치환됨)
    (식 중, Q1은 유리 또는 에테르화 히드록시 또는 반응성 에스테르화 히드록시 또는
    의 기임), b) 하기 일반식 (IIIa)의 화합물을 하기 일반식 (IIIb)의 화합물 또는 그의 염과 반응시키고,
    (식 중, 고리 A는 비치환되거나 또는 제1항에 기술된 바와 같이 치환됨)
    (식 중, X 및 Y는 제1항에 정의된 바와 같고, Q1은 유리 또는 에테르화 히드록시 또는 반응성 에스테르화 히드록시 또는
    의 기임), 필요한 경우 이 방법에 의해 얻을 수 있는 이성질체 혼합물을 분리시키고, 목적하는 이성질체를 단리시키고(또는) 이 방법에 의해 얻을 수 있는 유리 화합물 (I) 또는 (IA)를 염으로 전환시키거나 또는 이 방법에 의해 얻을 수 있는 화합물 (I) 또는 (IA)의 염을 유리 화합물 (I) 또는 (IA) 또는 상이한 염으로 전환시키는 것을 포함하는, 제1항 내지 제4항 중 어느 한 항에 따른 화합물의 제조 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950035296A 1994-10-14 1995-10-13 아로일-피페리딘유도체 KR100413985B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3091/94-2 1994-10-14
CH309194 1994-10-14

Publications (2)

Publication Number Publication Date
KR960014121A true KR960014121A (ko) 1996-05-22
KR100413985B1 KR100413985B1 (ko) 2004-03-26

Family

ID=4248427

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950035296A KR100413985B1 (ko) 1994-10-14 1995-10-13 아로일-피페리딘유도체

Country Status (23)

Country Link
US (1) US5965562A (ko)
EP (1) EP0707006B1 (ko)
JP (1) JP3022951B2 (ko)
KR (1) KR100413985B1 (ko)
CN (1) CN1066445C (ko)
AT (1) ATE178602T1 (ko)
AU (1) AU705851B2 (ko)
CA (1) CA2160444C (ko)
DE (1) DE59505575D1 (ko)
DK (1) DK0707006T3 (ko)
ES (1) ES2132580T3 (ko)
FI (1) FI114795B (ko)
GR (1) GR3030515T3 (ko)
HU (1) HUT74103A (ko)
IL (1) IL115572A (ko)
MX (1) MX9504349A (ko)
MY (1) MY114679A (ko)
NO (1) NO308034B1 (ko)
NZ (1) NZ280212A (ko)
RU (1) RU2158731C2 (ko)
SA (1) SA96160637B1 (ko)
TW (1) TW397825B (ko)
ZA (1) ZA958647B (ko)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
RU2156250C2 (ru) * 1995-04-24 2000-09-20 Новартис Аг Производные хромона, способ их получения и фармацевтическая композиция
AU2898297A (en) * 1996-05-24 1998-01-05 Novartis Ag Use of substance p antagonists for treating social phobia
AR018376A1 (es) 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
ES2198948T3 (es) * 1998-08-25 2004-02-01 Novartis Ag Usos de antagonistas de la substancia p para el tratamiento del sindrome de la fatiga cronica y/o de la fibromialgia.
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
EP1246806B1 (en) 1999-11-03 2008-02-27 AMR Technology, Inc. Arly- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
JP2001294582A (ja) * 2000-04-12 2001-10-23 Fuji Chemical Industries Ltd 光学活性アミノブチロラクトンの製造法
WO2002004455A2 (en) 2000-07-11 2002-01-17 Albany Molecular Research, Inc 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
GB0220953D0 (en) 2002-09-10 2002-10-23 Novartis Ag Organic compounds
GB2394417A (en) * 2002-10-24 2004-04-28 Novartis Ag Solid dispersion comprising a piperidine substance P antagonist and a carrier
AU2004232799A1 (en) 2003-04-18 2004-11-04 Eli Lilly And Company (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-HT1F agonists
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
EA020553B1 (ru) 2009-05-12 2014-12-30 Олбани Молекьюлар Рисерч, Инк. 7-([1,2,4]ТРИАЗОЛО[1,5-α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ И ПСИХИЧЕСКИХ РАССТРОЙСТВ
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
MX2012004377A (es) 2009-10-14 2012-06-01 Merck Sharp & Dohme Piperidinas sustituidas que aumentan la actividad de p53 y sus usos.
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2011292261B2 (en) 2010-08-17 2015-05-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
MX2015004041A (es) 2012-09-28 2015-07-06 Merck Sharp & Dohme Compuestos novedosos que son inhibidores de erk.
RU2660349C2 (ru) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Композиции и способы для лечения злокачественной опухоли
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN111808017B (zh) * 2020-08-05 2023-11-28 国家纳米科学中心 一种含氮杂环化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5145967A (en) * 1989-04-20 1992-09-08 Anaquest, Inc. Method for preparing 4-alkoxyalkyl-4-phenylaminopiperdines and derivatives thereof
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5126455A (en) * 1989-12-13 1992-06-30 Glaxo Inc. Preparation of substituted alkali metal piperidine-4-carboxylates
KR0160142B1 (ko) * 1990-05-31 1998-12-01 알렌 제이. 스피겔 치환된 피페리딘의 제조방법
JPH072740B2 (ja) * 1990-06-01 1995-01-18 フアイザー・インコーポレイテツド ３―アミノ―２―アリールキヌクリジン
AU651145B2 (en) * 1990-09-28 1994-07-14 Pfizer Inc. Fused ring analogs of nitrogen containing nonaromatic heterocycles
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives

Also Published As

Publication number Publication date
CN1133839A (zh) 1996-10-23
DE59505575D1 (de) 1999-05-12
NO954067D0 (no) 1995-10-13
IL115572A0 (en) 1996-01-19
HUT74103A (en) 1996-11-28
JP3022951B2 (ja) 2000-03-21
AU3317495A (en) 1996-04-26
CA2160444C (en) 2006-11-28
MX9504349A (es) 1997-03-29
IL115572A (en) 2001-05-20
KR100413985B1 (ko) 2004-03-26
DK0707006T3 (da) 1999-10-18
EP0707006A1 (de) 1996-04-17
ZA958647B (en) 1996-04-15
ES2132580T3 (es) 1999-08-16
CA2160444A1 (en) 1996-04-15
NO308034B1 (no) 2000-07-10
US5965562A (en) 1999-10-12
NZ280212A (en) 2001-10-26
GR3030515T3 (en) 1999-10-29
AU705851B2 (en) 1999-06-03
HU9502973D0 (en) 1995-12-28
SA96160637B1 (ar) 2005-06-14
FI114795B (fi) 2004-12-31
MY114679A (en) 2002-12-31
JPH08176145A (ja) 1996-07-09
RU2158731C2 (ru) 2000-11-10
CN1066445C (zh) 2001-05-30
NO954067L (no) 1996-04-15
ATE178602T1 (de) 1999-04-15
TW397825B (en) 2000-07-11
FI954829A (fi) 1996-04-15
FI954829A0 (fi) 1995-10-11
EP0707006B1 (de) 1999-04-07

Similar Documents

Publication Publication Date Title
KR960014121A (ko) 아로일-피페리딘 유도체
KR900018073A (ko) 피페라진 화합물
ES2213007T3 (es) Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2.
RU93005057A (ru) Фармацевтические соединения, производные тиенобензодиазепина, способ их получения, фармкомпозиция и их использование
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
PE79599A1 (es) Derivados de 5'-desoxicitidina
KR890006590A (ko) 4-아미노피리딘 유도체
ATE111460T1 (de) 2-(aminoalkyl)-5-(arylalkyl)1,3-dioxanderivate, ihre herstellung und ihre anwendung in der therapeutik.
UY28688A1 (es) Derivados de amida
ATE95816T1 (de) 2-((4-piperidinyl)methyl>-1,2,3,4tetrahydroisochinolin-derivate, ihre herstellung und ihre therapeutische verwendung.
AR012124A1 (es) Un procedimiento para la preparacion de derivados de tiazolidinadiona, derivados de tiazolidinadiona, su uso y preparados farmaceuticos que contienen a dichos derivados.
AR006301A1 (es) Derivados de oxazolidin-2-ona, procedimiento para prepararlos, medicamento constituido por dicho derivado y composicion farmaceutica que comprende a dicho derivado
KR920007995A (ko) 벤즈아미드 유도체
KR910011807A (ko) 4-벤질-5-페닐-2,4-디히드로-3h-1,2,4-트리아졸-3-온 및 진경제로서의 그 의 용도
KR880007494A (ko) 5-아릴-3h-1,2,4-트리아졸-3-온 및 진경제로서의 그들의 용도
AR002749A1 (es) Derivados de estiril bencimidazol y composicion farmaceutica que los comprende.
KR910021364A (ko) 신규 프로판아민, 그의 약리학적 특성 및 치료 목적, 특히 지사제로서의 용도
KR930021629A (ko) 피페라진 유도체
EA200101170A1 (ru) Галоидпроизводные 9-деоксо-9а-аза-9а-гомоэритромицина а
KR960014107A (ko) 피리미디닐 아크릴산 유도체
KR870009995A (ko) N- 디히드로인돌릴에틸-술폰아미드
KR910006292A (ko) 방향족 산의 n-아자비시클로 [3.3.0] 옥탄 아미드
ATE203533T1 (de) INDOLDERIVATE ALS PRODRUGS VON ß5-HT1-LIKEß REZEPTOR AGONISTEN
AR030879A1 (es) Uso de derivados del acido hidroperoxieicosatetraenoico luego de cirugia refractiva
AR011137A1 (es) Derivados de 4-aminoetoxiindazol, su uso para la preparacion de un medicamento y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20101208

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee